Publications – 2006

  • McLean DS, Cannon CP. A point-of-care assay to measure platelet aggregation in patients taking clopidogrel. Future Cardiol. 2006 May;2(3):255-67. doi: 10.2217/14796678.2.3.255.
  • Holmes DR, Coolong A, O’Shaughnessy C, Chauhan M, Van Langenhove G, Hall P, Vermeersch P, Verlee P, Popma JJ, Cutlip D, Kuntz RE. Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial. EuroIntervention. 2006 Aug;2(2):161-8.
  • Dawkins KD, Stone GW, Colombo A, Grube E, Ellis SG, Popma JJ, Serruys PW, Lam P, Koglin J, Russell ME. Integrated analysis of medically treated diabetic patients in the TAXUS(R) program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments. EuroIntervention. 2006 May;2(1):61-8.
  • Kim PK, Ellis TL, Stieber VW, McMullen KP, Shaw EG, McCoy TP, D’Agostino RB, Bourland JD, DeGuzman AF, Ekstrand KE, Raber MR, Tatter SB. Gamma Knife surgery targeting the resection cavity of brain metastasis that has progressed after whole-brain radiotherapy. J Neurosurg. 2006 Dec;105 Suppl:75-8. doi: 10.3171/sup.2006.105.7.75.
  • Kugelmass AD, Sadanandan S, Lakkis N, Dibattiste PM, Robertson DH, Demopoulos LA, Gibson CM, Weintraub WS, Murphy SA, Cannon CP; TACTICS TIMI-18 Investigators. Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: a report from TACTICS-TIMI 18. Crit Pathw Cardiol. 2006 Sep;5(3):167-72. doi: 10.1097/01.hpc.0000236218.07432.a6.
  • McLean DS, Cannon CP. The clinical potential of a point-of-care assay to assess interindividual variability in platelet aggregation among patients taking clopidogrel. Crit Pathw Cardiol. 2006 Jun;5(2):103-13. doi: 10.1097/01.hpc.0000220123.03088.51.
  • Steinberg BA, French WJ, Peterson ED, Frederick PD, Cannon CP; National Registry of Myocardial Infarction Investigators. Missed diagnosis of the diagnosis codes: comparison of International Classification of Diseases, 9th Revision coding and ST- versus non-ST-elevation myocardial infarction diagnosis in the National Registry of Myocardial Infarction. Crit Pathw Cardiol. 2006 Mar;5(1):59-63. doi: 10.1097/01.hpc.0000202298.34924.b1.
  • Elias MF, Sullivan LM, Elias PK, Vasan RS, D’Agostino RB Sr, Seshadri S, Au R, Wolf PA, Benjamin EJ. Atrial fibrillation is associated with lower cognitive performance in the Framingham offspring men. J Stroke Cerebrovasc Dis. 2006 Sep-Oct;15(5):214-22. doi: 10.1016/j.jstrokecerebrovasdis.2006.05.009.
  • Kashyap V, Turchin A, Morin L, Chang F, Li Q, Hongsermeier T. Creation of structured documentation templates using Natural Language Processing techniques. AMIA Annu Symp Proc. 2006;2006:977.
  • Greim J, Housman D, Turchin A, Orlowitz B, Eskin M, Abend A, Isikoff J, Einbinder J. The quality data warehouse: delivering answers on demand. AMIA Annu Symp Proc. 2006;2006:934.
  • Turchin A, Morin L, Semere LG, Kashyap V, Palchuk MB, Shubina M, Chang F, Li Q. Comparative evaluation of accuracy of extraction of medication information from narrative physician notes by commercial and academic natural language processing software packages. AMIA Annu Symp Proc. 2006:789-93.
  • Essebag V, Wylie JV Jr, Reynolds MR, Baldessin F, McClennen S, Shvilkin A, Germano J, Richardson A, Zimetbaum PJ, Josephson ME. Bi-directional electrical pulmonary vein isolation as an endpoint for ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2006 Nov;17(2):111-7. doi: 10.1007/s10840-006-9057-x. Epub 2007 Jan 18.
  • Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006 Dec 21;355(25):2631-9. doi: 10.1056/NEJMoa055373.
  • Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006 Dec 19;114(25):2871-91. doi: 10.1161/CIRCULATIONAHA.106.655761.
  • Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006 Dec 19;114(25):2850-70. doi: 10.1161/CIRCULATIONAHA.106.655688.
  • Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O’Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE; ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7. doi: 10.1016/j.jacc.2006.08.035. Epub 2006 Nov 28.
  • Charytan DM, Kuntz RE, Chhabra A, Cutlip DE. Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stenting. J Nephrol. 2006 Nov-Dec;19(6):764-70.
  • Cannon CP, Bhatt DL. Clinical trials update from the annual scientific session of the American College of Cardiology 2006. Am J Cardiol. 2006 Dec 18;98(12A):36Q-41Q. doi: 10.1016/j.amjcard.2006.09.023. Epub 2006 Oct 24.
  • Cannon CP. Evolving management of ST-segment elevation myocardial infarction: update on recent data. Am J Cardiol. 2006 Dec 18;98(12A):10Q-21Q. doi: 10.1016/j.amjcard.2006.09.026. Epub 2006 Nov 7.
  • Buxton AE, Calkins H, Callans DJ, DiMarco JP, Fisher JD, Greene HL, Haines DE, Hayes DL, Heidenreich PA, Miller JM, Poppas A, Prystowsky EN, Schoenfeld MH, Zimetbaum PJ, Heidenreich PA, Goff DC, Grover FL, Malenka DJ, Peterson ED, Radford MJ, Redberg RF; American College of Cardiology; American Heart Association Task Force on Clinical Data Standards; (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). J Am Coll Cardiol. 2006 Dec 5;48(11):2360-96. doi: 10.1016/j.jacc.2006.09.020.
  • Reynolds MR, Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study. Am Heart J. 2006 Dec;152(6):1097-103. doi: 10.1016/j.ahj.2006.08.011.
  • Shi L, Adams MM, Long A, Carter CC, Bennett C, Sonntag WE, Nicolle MM, Robbins M, D’Agostino R, Brunso-Bechtold JK. Spatial learning and memory deficits after whole-brain irradiation are associated with changes in NMDA receptor subunits in the hippocampus. Radiat Res. 2006 Dec;166(6):892-9. doi: 10.1667/RR0588.1.
  • Kirtane AJ, Gibson CM. Distal embolization of thrombus in acute myocardial infarction. Am J Med. 2006 Dec;119(12):e1-2. doi: 10.1016/j.amjmed.2006.08.019.
  • Uchida T, Bakhai A, Almonacid A, Shibata T, Cox B, Kuntz RE. A meta-analysis of randomized controlled trials of intracoronary gamma- and beta-radiation therapy for in-stent restenosis. Heart Vessels. 2006 Nov;21(6):368-74. doi: 10.1007/s00380-006-0919-z. Epub 2006 Nov 27.
  • American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology), Buxton AE, Calkins H, Callans DJ, DiMarco JP, Fisher JD, Greene HL, Haines DE, Hayes DL, Heidenreich PA, Miller JM, Poppas A, Prystowsky EN, Schoenfeld MH, Zimetbaum PJ, Goff DC, Grover FL, Malenka DJ, Peterson ED, Radford MJ, Redberg RF. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). Circulation. 2006 Dec 5;114(23):2534-70. doi: 10.1161/CIRCULATIONAHA.106.180199. Epub 2006 Nov 27.
  • Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?. Am J Cardiol. 2006 Dec 4;98(11A):18P-25P. doi: 10.1016/j.amjcard.2006.09.016. Epub 2006 Sep 29.
  • Brinster DR, Byrne M, Rogers CD, Baim DS, Simon DI, Couper GS, Cohn LH. Effectiveness of same day percutaneous coronary intervention followed by minimally invasive aortic valve replacement for aortic stenosis and moderate coronary disease (“hybrid approach”). Am J Cardiol. 2006 Dec 1;98(11):1501-3. doi: 10.1016/j.amjcard.2006.08.010. Epub 2006 Oct 13.
  • Moses JW, Nikolsky E, Mehran R, Cambier PA, Bachinsky WB, Leya F, Kuntz RE, Popma JJ, Schleckser P, Wang H, Cohen SA, Leon MB; SIRIUS 2.25 Investigators. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial. Am J Cardiol. 2006 Dec 1;98(11):1455-60. doi: 10.1016/j.amjcard.2006.06.047. Epub 2006 Oct 13.
  • Cutlip DE. Drug-eluting stent era: will we improve 5-year outcomes?. Coron Artery Dis. 2006 Dec;17(8):681-4. doi: 10.1097/01.mca.0000196795.77492.bc.
  • Ryan J, Cohen DJ, Pinto DS. Drug-eluting stents for ST[corrected]-elevation acute myocardial infarction: do we need randomized trials?. Coron Artery Dis. 2006 Dec;17(8):667-71. doi: 10.1097/MCA.0b013e3280111042.
  • Poon EG, Blumenfeld B, Hamann C, Turchin A, Graydon-Baker E, McCarthy PC, Poikonen J, Mar P, Schnipper JL, Hallisey RK, Smith S, McCormack C, Paterno M, Coley CM, Karson A, Chueh HC, Van Putten C, Millar SG, Clapp M, Bhan I, Meyer GS, Gandhi TK, Broverman CA. Design and implementation of an application and associated services to support interdisciplinary medication reconciliation efforts at an integrated healthcare delivery network. J Am Med Inform Assoc. 2006 Nov-Dec;13(6):581-92. doi: 10.1197/jamia.M2142.
  • Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18;368(9549):1771-81. doi: 10.1016/S0140-6736(06)69666-9.
  • Tsai TT, Fattori R, Trimarchi S, Isselbacher E, Myrmel T, Evangelista A, Hutchison S, Sechtem U, Cooper JV, Smith DE, Pape L, Froehlich J, Raghupathy A, Januzzi JL, Eagle KA, Nienaber CA; International Registry of Acute Aortic Dissection. Long-term survival in patients presenting with type B acute aortic dissection: insights from the International Registry of Acute Aortic Dissection. Circulation. 2006 Nov 21;114(21):2226-31. doi: 10.1161/CIRCULATIONAHA.106.622340. Epub 2006 Nov 13.
  • Neilan TG, Januzzi JL, Lee-Lewandrowski E, Ton-Nu TT, Yoerger DM, Jassal DS, Lewandrowski KB, Siegel AJ, Marshall JE, Douglas PS, Lawlor D, Picard MH, Wood MJ. Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston marathon. Circulation. 2006 Nov 28;114(22):2325-33. doi: 10.1161/CIRCULATIONAHA.106.647461. Epub 2006 Nov 13.
  • Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D’Agostino RB Sr, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006 Dec 6;296(21):2572-81. doi: 10.1001/jama.296.21.joc60158. Epub 2006 Nov 13.
  • Martinez-Rumayor A, Januzzi JL Jr. Non-ST segment elevation acute coronary syndromes: A comprehensive review. South Med J. 2006 Oct;99(10):1103-10. doi: 10.1097/01.smj.0000215764.22650.29.
  • Cannon CP, McLean DS. Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy. Am J Cardiol. 2006 Nov 20;98(10A):33N-38N. doi: 10.1016/j.amjcard.2006.09.012. Epub 2006 Oct 2.
  • Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol. 2006 Dec;17(6):626-30. doi: 10.1097/MOL.0b013e328010872d.
  • Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, Cutlip DE, Bates ER, Frederick PD, Miller DP, Carrozza JP Jr, Antman EM, Cannon CP, Gibson CM. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006 Nov 7;114(19):2019-25. doi: 10.1161/CIRCULATIONAHA.106.638353. Epub 2006 Oct 30.
  • Melanson SE, Green SM, Wood MJ, Neilan TG, Lewandrowski EL. Elevation of myeloperoxidase in conjunction with cardiac-specific markers after marathon running. Am J Clin Pathol. 2006 Dec;126(6):888-93. doi: 10.1309/1D62H6KRFTVQRJ0A.
  • Eurlings LW, Januzzi JL, Pinto YM. Is acute heart failure a highly prevalent orphan disease?. Eur Heart J. 2006 Nov;27(22):2619-20. doi: 10.1093/eurheartj/ehl332. Epub 2006 Oct 23.
  • Yan AT, Gibson CM, Larose E, Anavekar NS, Tsang S, Solomon SD, Reynolds G, Kwong RY. Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging. J Cardiovasc Magn Reson. 2006;8(6):831-7. doi: 10.1080/10976640600778049.
  • Tricoci P, Peterson ED, Mulgund J, Newby LK, Saucedo JF, Kleiman NS, Bhatt DL, Berger PB, Cannon CP, Cohen DJ, Hochman JS, Ohman EM, Gibler WB, Harrington RA, Smith SC Jr, Roe MT; CRUSADE Investigators. Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE). Am J Cardiol. 2006 Nov 1;98(9):1172-6. doi: 10.1016/j.amjcard.2006.05.047. Epub 2006 Aug 31.
  • Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006 Dec;70(11):2021-30. doi: 10.1038/sj.ki.5001934. Epub 2006 Oct 18.
  • Reynolds MR, Reyes JF, Fu Y, Bigio EH, Guillozet-Bongaarts AL, Berry RW, Binder LI. Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer’s disease and other tauopathies. J Neurosci. 2006 Oct 18;26(42):10636-45. doi: 10.1523/JNEUROSCI.2143-06.2006.
  • van Kimmenade RR, Januzzi JL Jr, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, Pinto YM. Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?. J Am Coll Cardiol. 2006 Oct 17;48(8):1621-7. doi: 10.1016/j.jacc.2006.06.056. Epub 2006 Sep 27.
  • Suk Danik J, Chasman DI, Cannon CP, Miller DT, Zee RY, Kozlowski P, Kwiatkowski DJ, Ridker PM. Influence of genetic variation in the C-reactive protein gene on the inflammatory response during and after acute coronary ischemia. Ann Hum Genet. 2006 Nov;70(Pt 6):705-16. doi: 10.1111/j.1469-1809.2006.00272.x.
  • McLaughlin MG, Zimetbaum PJ. Electrocardiographic predictors of arrhythmic death. Ann Noninvasive Electrocardiol. 2006 Oct;11(4):327-37. doi: 10.1111/j.1542-474X.2006.00125.x.
  • De Bartolo L, Morelli S, Rende M, Salerno S, Giorno L, Lopez LC, Favia P, d’Agostino R, Drioli E. Galactose derivative immobilized glow discharge processed polyethersulfone membranes maintain the liver cell metabolic activity. J Nanosci Nanotechnol. 2006 Aug;6(8):2344-53. doi: 10.1166/jnn.2006.514.
  • Cannon CP, Ballo MT, Zagars GK, Mirza AN, Lin PP, Lewis VO, Yasko AW, Benjamin RS, Pisters PW. Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer. 2006 Nov 15;107(10):2455-61. doi: 10.1002/cncr.22298.
  • Morello AM, Januzzi JL. Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure. Expert Rev Mol Diagn. 2006 Sep;6(5):649-62. doi: 10.1586/14737159.6.5.649.
  • Scirica BM, Cannon CP, Cooper R, Aster RH, Brassard J, McCabe CH, Charlesworth A, Skene AM, Braunwald E. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J Thromb Thrombolysis. 2006 Oct;22(2):95-102. doi: 10.1007/s11239-006-8669-4.
  • Gibson WJ, Gibson CM. The association of impaired myocardial perfusion and monocytosis with late recovery of left ventricular function following primary percutaneous coronary intervention. Eur Heart J. 2006 Nov;27(21):2487-8. doi: 10.1093/eurheartj/ehl267. Epub 2006 Sep 25.
  • Neilan TG, Ton-Nu TT, Jassal DS, Popovic ZB, Douglas PS, Halpern EF, Marshall JE, Thomas JD, Picard MH, Yoerger DM, Wood MJ. Myocardial adaptation to short-term high-intensity exercise in highly trained athletes. J Am Soc Echocardiogr. 2006 Oct;19(10):1280-5. doi: 10.1016/j.echo.2006.05.001.
  • Gregory SA, Ferencik M, Achenbach S, Yeh RW, Hoffmann U, Inglessis I, Cury RC, Nieman K, McNulty IA, Laffan JA, Pomerantsev EV, Brady TJ, Semigran MJ, Jang IK. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. Am J Cardiol. 2006 Oct 1;98(7):877-84. doi: 10.1016/j.amjcard.2006.04.027. Epub 2006 Aug 4.
  • Ray KK, Morrow DA, Shui A, Rifai N, Cannon CP. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22). Am J Cardiol. 2006 Oct 1;98(7):861-5. doi: 10.1016/j.amjcard.2006.04.024. Epub 2006 Aug 4.
  • Gibson CM, Kirtane AJ, Morrow DA, Palabrica TM, Murphy SA, Stone PH, Scirica BM, Jennings LK, Herrmann HC, Cohen DJ, McCabe CH, Braunwald E; TIMI Study Group. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). Am Heart J. 2006 Oct;152(4):756-61. doi: 10.1016/j.ahj.2006.04.016.
  • Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, Kazziha S, Rokos I, Shammas NW, Palabrica TM, Fish P, McCabe CH, Braunwald E; TIMI Study Group. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. Am Heart J. 2006 Oct;152(4):668-75. doi: 10.1016/j.ahj.2006.06.003.
  • Patel MR, Chen AY, Peterson ED, Newby LK, Pollack CV Jr, Brindis RG, Gibson CM, Kleiman NS, Saucedo JF, Bhatt DL, Gibler WB, Ohman EM, Harrington RA, Roe MT. Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines (CRUSADE) initiative. Am Heart J. 2006 Oct;152(4):641-7. doi: 10.1016/j.ahj.2006.02.035.
  • Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006 Oct;152(4):627-35. doi: 10.1016/j.ahj.2006.04.012.
  • Ray KK, Cannon CP. Intensive statin therapy for treating acute coronary syndromes. Expert Opin Investig Drugs. 2006 Oct;15(10):1151-9. doi: 10.1517/13543784.15.10.1151.
  • Quatromoni PA, Pencina M, Cobain MR, Jacques PF, D’Agostino RB. Dietary quality predicts adult weight gain: findings from the Framingham Offspring Study. Obesity (Silver Spring). 2006 Aug;14(8):1383-91. doi: 10.1038/oby.2006.157.
  • Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, Gutkind JS. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia. 2006 Sep;8(9):733-46. doi: 10.1593/neo.06274.
  • van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006 Sep 19;48(6):1217-24. doi: 10.1016/j.jacc.2006.03.061. Epub 2006 Aug 28.
  • Piazza G, Carrozza JP Jr, Zimetbaum PJ. An unusual explanation for episodic dyspnea. Circulation. 2006 Sep 12;114(11):e485-6. doi: 10.1161/CIRCULATIONAHA.105.604900.
  • Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006 Oct;27(19):2323-9. doi: 10.1093/eurheartj/ehl220. Epub 2006 Sep 5.
  • Göhler A, Januzzi JL, Worrell SS, Osterziel KJ, Gazelle GS, Dietz R, Siebert U. A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. J Card Fail. 2006 Sep;12(7):554-67. doi: 10.1016/j.cardfail.2006.03.003.
  • Tseng JF, Ballo MT, Langstein HN, Wayne JD, Cormier JN, Hunt KK, Feig BW, Yasko AW, Lewis VO, Lin PP, Cannon CP, Zagars GK, Pollock RE, Pisters PW. The effect of preoperative radiotherapy and reconstructive surgery on wound complications after resection of extremity soft-tissue sarcomas. Ann Surg Oncol. 2006 Sep;13(9):1209-15. doi: 10.1245/s10434-006-9028-6. Epub 2006 Sep 3.
  • Siebert U, Januzzi JL Jr, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol. 2006 Sep 15;98(6):800-5. doi: 10.1016/j.amjcard.2006.06.005. Epub 2006 Aug 2.
  • Gibson CM, Ly HQ, Murphy SA, Ciaglo LN, Southard MC, Stein EB, Buros JL, Sabatine MS, Cannon CP; TIMI Study Group. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am J Cardiol. 2006 Sep 15;98(6):761-3. doi: 10.1016/j.amjcard.2006.03.062. Epub 2006 Aug 2.
  • Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, Carrozza JP Jr, Cohen DJ, Ho KK, Cutlip DE. Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol. 2006 Sep 15;98(6):718-21. doi: 10.1016/j.amjcard.2006.03.059. Epub 2006 Jul 13.
  • Frisch DR, Kwaku KF, Allocco DJ, Zimetbaum PJ. Atrioventricular nodal reentrant tachycardia in two siblings with Wolfram syndrome. J Cardiovasc Electrophysiol. 2006 Sep;17(9):1029-31. doi: 10.1111/j.1540-8167.2006.00522.x.
  • Eckart RE, Gula LJ, Reynolds MR, Shry EA, Maisel WH. Mortality following defibrillator implantation in patients with renal insufficiency. J Cardiovasc Electrophysiol. 2006 Sep;17(9):940-3. doi: 10.1111/j.1540-8167.2006.00550.x.
  • Melanson SE, Laposata M, Camargo CA Jr, Chen AA, Tung R, Krauser D, Anwaruddin S, Baggish A, Cameron R, Sluss P, Lewandrowski KB, Lee-Lewandrowski E, Januzzi JL. Combination of D-dimer and amino-terminal pro-B-type natriuretic Peptide testing for the evaluation of dyspneic patients with and without acute pulmonary embolism. Arch Pathol Lab Med. 2006 Sep;130(9):1326-9. doi: 10.1043/1543-2165(2006)130[1326:CODAAP]2.0.CO;2.
  • Turchin A, Kolatkar NS, Grant RW, Makhni EC, Pendergrass ML, Einbinder JS. Using regular expressions to abstract blood pressure and treatment intensification information from the text of physician notes. J Am Med Inform Assoc. 2006 Nov-Dec;13(6):691-5. doi: 10.1197/jamia.M2078. Epub 2006 Aug 23.
  • Murabito JM, Guo CY, Fox CS, D’Agostino RB. Heritability of the ankle-brachial index: the Framingham Offspring study. Am J Epidemiol. 2006 Nov 15;164(10):963-8. doi: 10.1093/aje/kwj295. Epub 2006 Aug 23.
  • Yeh RW, Triadafilopoulos G. Injection therapies for nonbleeding disorders of the GI tract. Gastrointest Endosc. 2006 Sep;64(3):399-411; quiz 389-92. doi: 10.1016/j.gie.2006.04.010.
  • Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006 Sep 1;98(5):681-4. doi: 10.1016/j.amjcard.2006.03.054. Epub 2006 Jul 7.
  • Charytan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J. 2006 Sep;152(3):558-64. doi: 10.1016/j.ahj.2006.02.021.
  • Krauser DG, Chen AA, Tung R, Anwaruddin S, Baggish AL, Januzzi JL Jr. Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail. 2006 Aug;12(6):452-7. doi: 10.1016/j.cardfail.2006.04.005.
  • Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Münzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006 Aug 22;114(8):798-806. doi: 10.1161/CIRCULATIONAHA.105.591206. Epub 2006 Aug 14.
  • Millen BE, Pencina MJ, Kimokoti RW, Zhu L, Meigs JB, Ordovas JM, D’Agostino RB. Nutritional risk and the metabolic syndrome in women: opportunities for preventive intervention from the Framingham Nutrition Study. Am J Clin Nutr. 2006 Aug;84(2):434-41. doi: 10.1093/ajcn/84.1.434.
  • van der Steen JT, Mehr DR, Kruse RL, Sherman AK, Madsen RW, D’Agostino RB, Ooms ME, van der Wal G, Ribbe MW. Predictors of mortality for lower respiratory infections in nursing home residents with dementia were validated transnationally. J Clin Epidemiol. 2006 Sep;59(9):970-9. doi: 10.1016/j.jclinepi.2005.12.005. Epub 2006 May 23.
  • Turco MA, Buchbinder M, Popma JJ, Weissman NJ, Mann T, Doucet S, Johnson WL Jr, Greenberg JD, Leadley K, Russell ME. Pivotal, randomized U.S. study of the Symbiottrade mark covered stent system in patients with saphenous vein graft disease: eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv. 2006 Sep;68(3):379-88. doi: 10.1002/ccd.20873.
  • Saenz AJ, Lee-Lewandrowski E, Wood MJ, Neilan TG, Siegel AJ, Januzzi JL, Lewandrowski KB. Measurement of a plasma stroke biomarker panel and cardiac troponin T in marathon runners before and after the 2005 Boston marathon. Am J Clin Pathol. 2006 Aug;126(2):185-9. doi: 10.1309/D7QU-F0HJ-MCYY-YY5A.
  • Ray KK, Bach RG, Cannon CP, Cairns R, Kirtane AJ, Wiviott SD, McCabe CH, Braunwald E, Gibson CM; PROVE IT-TIMI 22 Investigators. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J. 2006 Oct;27(19):2310-6. doi: 10.1093/eurheartj/ehl180. Epub 2006 Aug 3.
  • Baim DS. Approaches to mechanical coronary thrombectomy. J Invasive Cardiol. 2006 Jul;18 Suppl C:28C-31C.
  • Arnlöv J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, D’Agostino RB Sr, Bhasin S, Vasan RS. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug 1;145(3):176-84. doi: 10.7326/0003-4819-145-3-200608010-00005.
  • O’Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, Sabatine MS. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006 Aug 8;114(6):550-7. doi: 10.1161/CIRCULATIONAHA.106.641936. Epub 2006 Jul 31.
  • Sperling RT, Ho K, James D, Laham R, Gibson M, Carrozza J. Treatment of stent-jailed side branch stenoses with rotational atherectomy. J Invasive Cardiol. 2006 Aug;18(8):354-8.
  • Jonas M, Fang JC, Wang JC, Giri S, Elian D, Har-Zahav Y, Ly H, Seifert PA, Popma JJ, Rogers C. In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. J Am Coll Cardiol. 2006 Aug 1;48(3):453-61. doi: 10.1016/j.jacc.2006.01.081. Epub 2006 Jul 12.
  • Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006 Aug 1;48(3):438-45. doi: 10.1016/j.jacc.2006.04.070. Epub 2006 Jul 12.
  • Foo SY, Everett BM, Yeh RW, Criss D, Laposata M, Van Cott EM, Jang IK. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am Heart J. 2006 Aug;152(2):290.e1-7. doi: 10.1016/j.ahj.2006.04.028.
  • Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC, Lefevre G, Mutrie D, Sinha MK, Uettwiller-Geiger D, Pollack CV. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J. 2006 Aug;152(2):253-62. doi: 10.1016/j.ahj.2005.12.024.
  • Cannon CP, Curtis SP, Bolognese JA, Laine L; MEDAL Steering Committee. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J. 2006 Aug;152(2):237-45. doi: 10.1016/j.ahj.2006.05.024.
  • Wiviott SD, Cannon CP. Update on lipid-lowering therapy and LDL-cholesterol targets. Nat Clin Pract Cardiovasc Med. 2006 Aug;3(8):424-36. doi: 10.1038/ncpcardio0613.
  • Thomas KE, Pinto DS. Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?. Nat Clin Pract Cardiovasc Med. 2006 Aug;3(8):416-7. doi: 10.1038/ncpcardio0628.
  • Yeh RW, Everett BM, Foo SY, Dorer DJ, Laposata M, Van Cott EM, Jang IK. Predictors for the development of elevated anti-heparin/platelet factor 4 antibody titers in patients undergoing cardiac catheterization. Am J Cardiol. 2006 Aug 1;98(3):419-21. doi: 10.1016/j.amjcard.2006.02.048. Epub 2006 Jun 12.
  • van Kimmenade RR, Pinto YM, Bayes-Genis A, Lainchbury JG, Richards AM, Januzzi JL Jr. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol. 2006 Aug 1;98(3):386-90. doi: 10.1016/j.amjcard.2006.02.043. Epub 2006 Jun 12.
  • Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O’Neill WW, Lansky AJ, Griffin JJ; CADILLAC Investigators. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial). Am J Cardiol. 2006 Aug 1;98(3):331-7. doi: 10.1016/j.amjcard.2006.01.102. Epub 2006 Jun 9.
  • Huffman JC, Smith FA, Blais MA, Beiser ME, Januzzi JL, Fricchione GL. Recognition and treatment of depression and anxiety in patients with acute myocardial infarction. Am J Cardiol. 2006 Aug 1;98(3):319-24. doi: 10.1016/j.amjcard.2006.02.033. Epub 2006 Jun 12.
  • Kirtane AJ, Vafai JJ, Murphy SA, Aroesty JM, Sabatine MS, Cannon CP, Gibson CM; TIMI Study Group. Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy. Eur Heart J. 2006 Sep;27(17):2040-5. doi: 10.1093/eurheartj/ehl149. Epub 2006 Jul 17.
  • Bainey KR, Kalia N, Carter D, Hrynchyshyn G, Kasza L, Lee TK, Wirzba B, Senaratne MP. Right precordial leads and lead aVR at exercise electrocardiography: does it change test results?. Ann Noninvasive Electrocardiol. 2006 Jul;11(3):247-52. doi: 10.1111/j.1542-474X.2006.00111.x.
  • Mehta RH, Roe MT, Mulgund J, Ohman EM, Cannon CP, Gibler WB, Pollack CV Jr, Smith SC Jr, Ferguson TB, Peterson ED. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2006 Jul 18;48(2):281-6. doi: 10.1016/j.jacc.2006.04.029. Epub 2006 Jun 21.
  • Lee DS, Pencina MJ, Benjamin EJ, Wang TJ, Levy D, O’Donnell CJ, Nam BH, Larson MG, D’Agostino RB, Vasan RS. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006 Jul 13;355(2):138-47. doi: 10.1056/NEJMoa052948.
  • Cooper CJ, Murphy TP, Matsumoto A, Steffes M, Cohen DJ, Jaff M, Kuntz R, Jamerson K, Reid D, Rosenfield K, Rundback J, D’Agostino R, Henrich W, Dworkin L. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006 Jul;152(1):59-66. doi: 10.1016/j.ahj.2005.09.011.
  • Coolong A, Mauri L. Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped?. Curr Cardiol Rep. 2006 Jul;8(4):267-71. doi: 10.1007/s11886-006-0057-3.
  • Scirica BM, Sabatine MS, Morrow DA, Gibson CM, Murphy SA, Wiviott SD, Giugliano RP, McCabe CH, Cannon CP, Braunwald E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 4;48(1):37-42. doi: 10.1016/j.jacc.2006.02.052. Epub 2006 Jun 12.
  • Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Mehran R, Na Y, Turco M, Caputo R, Popma JJ, Cutlip DE, Russell ME, Cohen DJ; TAXUS-IV Investigators. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006 Jul 4;48(1):32-6. doi: 10.1016/j.jacc.2006.02.060. Epub 2006 Jun 9.
  • Kereiakes DJ, Wang H, Popma JJ, Kuntz RE, Donohoe DJ, Schofer J, Schampaert E, Meier B, Leon MB, Moses JW. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol. 2006 Jul 4;48(1):21-31. doi: 10.1016/j.jacc.2006.02.058. Epub 2006 Jun 12.
  • Pérez de Prado A, Fernández-Vázquez F, Cuellas-Ramón JC, Gibson CM. [Coronary angiography: beyond coronary anatomy]. Rev Esp Cardiol. 2006 Jun;59(6):596-608.
  • Mega JL, Morrow DA, Cannon CP, Murphy S, Cairns R, Ridker PM, Braunwald E. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis. 2006 Aug;22(1):71-6. doi: 10.1007/s11239-006-8081-0.
  • Deibele AJ, Kirtane AJ, Pinto DS, Lucca MJ, Neva C, Shui A, Murphy SA, Tcheng JE, Gibson CM. Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. J Thromb Thrombolysis. 2006 Aug;22(1):47-50. doi: 10.1007/s11239-006-7454-8.
  • Gibson CM, Zorkun C, Molhoek P, Zmudka K, Greenberg M, Mueller H, Wesdorp J, Louwerenburg H, Niederman A, Westenburg J, Bikkina M, Batty J, de Winter J, Murphy SA, McCabe CH. Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial. J Thromb Thrombolysis. 2006 Aug;22(1):13-21. doi: 10.1007/s11239-006-8080-1.
  • Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D’Agostino RB Sr. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation. 2006 Jun 27;113(25):2914-8. doi: 10.1161/CIRCULATIONAHA.106.613828. Epub 2006 Jun 19.
  • Schampaert E, Moses JW, Schofer J, Schlüter M, Gershlick AH, Cohen EA, Palisaitis DA, Breithardt G, Donohoe DJ, Wang H, Popma JJ, Kuntz RE, Leon MB; SIRIUS, E- and C-SIRIUS Investigators. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol. 2006 Jul 1;98(1):36-41. doi: 10.1016/j.amjcard.2006.01.049. Epub 2006 May 4.
  • Ly HQ, Kirtane AJ, Murphy SA, Buros J, Cannon CP, Braunwald E, Gibson CM; TIMI Study Group. Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials). Am J Cardiol. 2006 Jul 1;98(1):1-5. doi: 10.1016/j.amjcard.2006.01.046. Epub 2006 Apr 27.
  • Popma JJ, Tulli M. Drug-eluting stents. Cardiol Clin. 2006 May;24(2):217-31, vi. doi: 10.1016/j.ccl.2006.04.001.
  • Tung RH, Camargo CA Jr, Krauser D, Anwaruddin S, Baggish A, Chen A, Januzzi JL Jr. Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann Emerg Med. 2006 Jul;48(1):66-74. doi: 10.1016/j.annemergmed.2005.12.022. Epub 2006 Feb 17.
  • Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, Simon AW. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006 Jun 20;47(12):2493-7. doi: 10.1016/j.jacc.2006.02.049. Epub 2006 May 30.
  • Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, Cohen DJ, Peterson E, Lakkis N, Herrmann HC, Palabrica TM, Gibson CM; TIMI Study Group. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006 Jun 20;47(12):2374-9. doi: 10.1016/j.jacc.2005.09.080. Epub 2006 May 30.
  • Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E; TIMI Study Group. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006 Jun 20;47(12):2364-73. doi: 10.1016/j.jacc.2005.12.077.
  • Yeh RW, Jang IK. Argatroban: update. Am Heart J. 2006 Jun;151(6):1131-8. doi: 10.1016/j.ahj.2005.09.002.
  • Pinto DS, Southard M, Ciaglo L, Gibson CM. Door-to-balloon delays with percutaneous coronary intervention in ST-elevation myocardial infarction. Am Heart J. 2006 Jun;151(6 Suppl):S24-9. doi: 10.1016/j.ahj.2006.04.010.
  • Geier AB, Rozin P, Doros G. Unit bias. A new heuristic that helps explain the effect of portion size on food intake. Psychol Sci. 2006 Jun;17(6):521-5. doi: 10.1111/j.1467-9280.2006.01738.x.
  • Mandapaka S, D’Agostino R Jr, Hundley WG. Does late gadolinium enhancement predict cardiac events in patients with ischemic cardiomyopathy?. Circulation. 2006 Jun 13;113(23):2676-8. doi: 10.1161/CIRCULATIONAHA.106.631432.
  • Clark PE, Hall MC, Borden LS Jr, Miller AA, Hu JJ, Lee WR, Stindt D, D’Agostino R Jr, Lovato J, Harmon M, Torti FM. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology. 2006 Jun;67(6):1257-61. doi: 10.1016/j.urology.2005.12.035.
  • Brindle P, May M, Gill P, Cappuccio F, D’Agostino R Sr, Fischbacher C, Ebrahim S. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart. 2006 Nov;92(11):1595-602. doi: 10.1136/hrt.2006.092346. Epub 2006 Jun 8.
  • Jassal DS, Nomura CH, Neilan TG, Holmvang G, Fatima U, Januzzi J, Brady TJ, Cury RC. Delayed enhancement cardiac MR imaging in noncompaction of left ventricular myocardium. J Cardiovasc Magn Reson. 2006;8(3):489-91. doi: 10.1080/10976640600599502.
  • Mauri L, Rogers C, Baim DS. Devices for distal protection during percutaneous coronary revascularization. Circulation. 2006 Jun 6;113(22):2651-6. doi: 10.1161/CIRCULATIONAHA.105.551770.
  • Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E; PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 6;47(11):2326-31. doi: 10.1016/j.jacc.2006.03.034. Epub 2006 May 4.
  • Elmariah S, Goldberg LR, Allen MT, Kao A. Effects of gender on peak oxygen consumption and the timing of cardiac transplantation. J Am Coll Cardiol. 2006 Jun 6;47(11):2237-42. doi: 10.1016/j.jacc.2005.11.089.
  • Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, D’Agostino RB. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006 Aug;91(8):2906-12. doi: 10.1210/jc.2006-0594. Epub 2006 May 30.
  • Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, Furlott J, Gonzalez EJ, Yant LJ, Maness NJ, May GE, Soma T, Reynolds MR, Rakasz E, Rudersdorf R, McDermott AB, O’Connor DH, Friedrich TC, Allison DB, Patki A, Picker LJ, Burton DR, Lin J, Huang L, Patel D, Heindecker G, Fan J, Citron M, Horton M, Wang F, Liang X, Shiver JW, Casimiro DR, Watkins DI. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol. 2006 Jun;80(12):5875-85. doi: 10.1128/JVI.00171-06.
  • Cutlip DE. Drug-eluting stent era: will we improve 5-year outcomes?. Coron Artery Dis. 2006 May;17(3):289-92. doi: 10.1097/00019501-200605000-00014.
  • Moussa ID, Moses JW, Kuntz RE, Holmes DR, Popma JJ, Teirstein PS, Wong SC, Leon MB. The fate of patients with clinical recurrence after sirolimus-eluting stent implantation (a two-year follow-up analysis from the SIRIUS trial). Am J Cardiol. 2006 Jun 1;97(11):1582-4. doi: 10.1016/j.amjcard.2005.12.048. Epub 2006 Apr 6.
  • Bhadriraju S, Ray KK, DeFranco AC, Barber K, Bhadriraju P, Murphy SA, Morrow DA, McCabe CH, Gibson CM, Cannon CP, Braunwald E. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Am J Cardiol. 2006 Jun 1;97(11):1573-7. doi: 10.1016/j.amjcard.2005.12.046. Epub 2006 Apr 4.
  • Davidson MJ, White JK, Baim DS. Percutaneous therapies for valvular heart disease. Cardiovasc Pathol. 2006 May-Jun;15(3):123-9. doi: 10.1016/j.carpath.2006.02.004.
  • Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol. 2006 May 16;47(10):1919-26. doi: 10.1016/j.jacc.2005.12.067. Epub 2006 Apr 24.
  • Dumaine R, Gibson CM, Murphy SA, Southard M, Ly HQ, McCabe CH, Giugliano RP, Cannon CP, Antman EM, Braunwald E; Thrombolysis in Myocardial Infarction (TIMI) Study Group. Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May;8(5):315-22. doi: 10.1111/j.1524-6175.2006.05384.x.
  • Fox CS, Guo CY, Larson MG, Vasan RS, Parise H, O’Donnell CJ, D’Agostino RB Sr, Keaney JF Jr, Benjamin EJ. Relations of inflammation and novel risk factors to valvular calcification. Am J Cardiol. 2006 May 15;97(10):1502-5. doi: 10.1016/j.amjcard.2005.11.086. Epub 2006 Mar 29.
  • Gibson CM, Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, Ray KK, Herrmann HC, Lakkis N, Kovach R, French W, Blankenship J, Lui HH, Palabrica T, Jennings LK, Cohen DJ, Morrow DA; TIMI Study Group. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol. 2006 May 15;97(10):1473-7. doi: 10.1016/j.amjcard.2005.12.037. Epub 2006 Mar 29.
  • Gaziano JM, Gibson CM. Potential for drug-drug interactions in patients taking analgesics for mild-to-moderate pain and low-dose aspirin for cardioprotection. Am J Cardiol. 2006 May 8;97(9A):23-9. doi: 10.1016/j.amjcard.2006.02.020. Epub 2006 Mar 30.
  • Huffman JC, Smith FA, Blais MA, Beiser ME, Januzzi JL, Fricchione GL. Rapid screening for major depression in post-myocardial infarction patients: an investigation using Beck Depression Inventory II items. Heart. 2006 Nov;92(11):1656-60. doi: 10.1136/hrt.2005.087213. Epub 2006 Apr 27.
  • Atar S, Cannon CP, Murphy SA, Rosanio S, Uretsky BF, Birnbaum Y. Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial. Am Heart J. 2006 May;151(5):976.e1-6. doi: 10.1016/j.ahj.2006.02.013.
  • Shukla GJ, Zimetbaum PJ. Cardiology patient page. Syncope. Circulation. 2006 Apr 25;113(16):e715-7. doi: 10.1161/CIRCULATIONAHA.105.602250.
  • Ahmed S, Antman EM, Murphy SA, Giugliano RP, Cannon CP, White H, Morrow DA, Braunwald E. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006 Apr;21(2):119-29. doi: 10.1007/s11239-006-5485-9.
  • Tricoci P, Roe MT, Mulgund J, Newby LK, Smith SC Jr, Pollack CV Jr, Fintel DJ, Cannon CP, Bhatt DL, Gibler WB, Ohman EM, Peterson ED, Harrington RA. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med. 2006 Apr 10;166(7):806-11. doi: 10.1001/archinte.166.7.806.
  • Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI. Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J Neurochem. 2006 May;97(4):1005-14. doi: 10.1111/j.1471-4159.2006.03784.x. Epub 2006 Apr 5.
  • Turchin A, Guo CZ, Adler GK, Ricchiuti V, Kohane IS, Williams GH. Effect of acute aldosterone administration on gene expression profile in the heart. Endocrinology. 2006 Jul;147(7):3183-9. doi: 10.1210/en.2005-1674. Epub 2006 Apr 6.
  • Baggish AL, Januzzi JL. Cost effectiveness of natriuretic peptide measurement in the primary care setting: have we found the gatekeeper for the evaluation of dyspneic outpatients?. Congest Heart Fail. 2006 Mar-Apr;12(2):108-9. doi: 10.1111/j.1527-5299.2006.05359.x.
  • Dhingra R, Pencina MJ, Wang TJ, Nam BH, Benjamin EJ, Levy D, Larson MG, Kannel WB, D’Agostino RB Sr, Vasan RS. Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study. Hypertension. 2006 May;47(5):861-7. doi: 10.1161/01.HYP.0000217141.20163.23. Epub 2006 Apr 3.
  • Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev. 2006 Jun 3;58(3):437-46. doi: 10.1016/j.addr.2006.01.021. Epub 2006 Mar 6.
  • Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, Cohen BM, Ellis SG, Coleman P, Hill C, Shi C, Cutlip DE, Kuntz RE, Moses JW. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol. 2006 Apr 4;47(7):1350-5. doi: 10.1016/j.jacc.2005.11.077. Epub 2006 Mar 20.
  • Halkin A, Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, Haber RH, Cambier PA, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA, Mehran R, Stone GW. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial. Am Heart J. 2006 Apr;151(4):915.e1-7. doi: 10.1016/j.ahj.2005.09.018.
  • Svensson L, Aasa M, Dellborg M, Gibson CM, Kirtane A, Herlitz J, Ohlsson A, Karlsson T, Grip L. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial. Am Heart J. 2006 Apr;151(4):798.e1-7. doi: 10.1016/j.ahj.2005.09.013.
  • Festa A, Williams K, D’Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes. 2006 Apr;55(4):1114-20. doi: 10.2337/diabetes.55.04.06.db05-1100.
  • Reynolds MR, Lukas TJ, Berry RW, Binder LI. Peroxynitrite-mediated tau modifications stabilize preformed filaments and destabilize microtubules through distinct mechanisms. Biochemistry. 2006 Apr 4;45(13):4314-26. doi: 10.1021/bi052142h.
  • Liddicoat JR, De La Torre R, Ho KK, Nathan S, Levitsky S, Krempin J, Sellke F. Initial impact of drug-eluting stents on coronary artery bypass graft surgery. Ann Thorac Surg. 2006 Apr;81(4):1239-42; discussion 1242. doi: 10.1016/j.athoracsur.2005.08.012.
  • Teirstein PS, Price MJ, Mathur VS, Madyoon H, Sawhney N, Baim DS. Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. Am J Cardiol. 2006 Apr 1;97(7):1076-81. doi: 10.1016/j.amjcard.2005.10.053. Epub 2006 Feb 28.
  • Neilan TG, Yoerger DM, Douglas PS, Marshall JE, Halpern EF, Lawlor D, Picard MH, Wood MJ. Persistent and reversible cardiac dysfunction among amateur marathon runners. Eur Heart J. 2006 May;27(9):1079-84. doi: 10.1093/eurheartj/ehi813. Epub 2006 Mar 22.
  • O’Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006 Apr 11;113(14):1745-52. doi: 10.1161/CIRCULATIONAHA.105.612630. Epub 2006 Mar 14.
  • Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, Califf R, Braunwald E. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation. 2006 Mar 21;113(11):1406-14. doi: 10.1161/CIRCULATIONAHA.105.586347. Epub 2006 Mar 13.
  • D’Agostino RB. Risk prediction and finding new independent prognostic factors. J Hypertens. 2006 Apr;24(4):643-5. doi: 10.1097/01.hjh.0000217845.57466.cc.
  • Holmes DR Jr, Teirstein P, Satler L, Sketch M, O’Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA; SISR Investigators. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA. 2006 Mar 15;295(11):1264-73. doi: 10.1001/jama.295.11.1264. Epub 2006 Mar 12.
  • Stone GW, Ellis SG, O’Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME; TAXUS V ISR Investigators. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006 Mar 15;295(11):1253-63. doi: 10.1001/jama.295.11.1253. Epub 2006 Mar 12.
  • D’Agostino RB Sr, Campbell M, Greenhouse J. Non-inferiority trials: continued advancements in concepts and methodology (special papers for the 25th Anniversary of Statistics in Medicine 25(7)). Stat Med. 2006 Apr 15;25(7):1097-9. doi: 10.1002/sim.2553.
  • Chen AA, Wood MJ, Krauser DG, Baggish AL, Tung R, Anwaruddin S, Picard MH, Januzzi JL. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J. 2006 Apr;27(7):839-45. doi: 10.1093/eurheartj/ehi811. Epub 2006 Mar 1.
  • Rosso F, Marino G, Muscariello L, Cafiero G, Favia P, D’Aloia E, d’Agostino R, Barbarisi A. Adhesion and proliferation of fibroblasts on RF plasma-deposited nanostructured fluorocarbon coatings: evidence of FAK activation. J Cell Physiol. 2006 Jun;207(3):636-43. doi: 10.1002/jcp.20595.
  • Januzzi JL, Morss A, Tung R, Pino R, Fifer MA, Thompson BT, Lee-Lewandrowski E. Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit Care. 2006 Feb;10(1):R37. doi: 10.1186/cc4839.
  • Baim DS, Kwong RY. Is magnetic resonance image guidance the key to opening chronic total occlusions?. Circulation. 2006 Feb 28;113(8):1053-5. doi: 10.1161/CIRCULATIONAHA.105.609263.
  • Gelfand EV, Cannon CP. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs. 2006 Mar;15(3):307-15. doi: 10.1517/13543784.15.3.307.
  • Baim DS, Mauri L, Cutlip DC. Drug-eluting stenting for unprotected left main coronary artery disease: are we ready to replace bypass surgery?. J Am Coll Cardiol. 2006 Feb 21;47(4):878-81. doi: 10.1016/j.jacc.2005.12.016. Epub 2006 Jan 6.
  • Januzzi JL Jr. Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleve Clin J Med. 2006 Feb;73(2):149-52, 155-7. doi: 10.3949/ccjm.73.2.149.
  • Januzzi JL Jr, Sakhuja R, O’donoghue M, Baggish AL, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA Jr, Lloyd-Jones DM. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006 Feb 13;166(3):315-20. doi: 10.1001/archinte.166.3.315.
  • Baim DS, Mehran R, Kereiakes DJ, Gross TP, Simons M, Malenka D, Kaplan AV. Postmarket surveillance for drug-eluting coronary stents: a comprehensive approach. Circulation. 2006 Feb 14;113(6):891-7. doi: 10.1161/CIRCULATIONAHA.105.569657.
  • Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, D’Agostino RB, DeCarli C. Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol. 2006 Feb;63(2):246-50. doi: 10.1001/archneur.63.2.246.
  • Elosua R, Ordovas JM, Cupples LA, Lai CQ, Demissie S, Fox CS, Polak JF, Wolf PA, D’Agostino RB Sr, O’Donnell CJ. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res. 2006 May;47(5):990-6. doi: 10.1194/jlr.M500446-JLR200. Epub 2006 Feb 11.
  • Lloyd-Jones DM, Leip EP, Larson MG, D’Agostino RB, Beiser A, Wilson PW, Wolf PA, Levy D. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006 Feb 14;113(6):791-8. doi: 10.1161/CIRCULATIONAHA.105.548206. Epub 2006 Feb 6.
  • Reynolds MR, Shah J, Essebag V, Olshansky B, Friedman PA, Hadjis T, Lemery R, Bahnson TD, Cannom DS, Josephson ME, Zimetbaum P. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006 Feb 15;97(4):538-43. doi: 10.1016/j.amjcard.2005.09.086. Epub 2006 Jan 4.
  • Estes JD, Li Q, Reynolds MR, Wietgrefe S, Duan L, Schacker T, Picker LJ, Watkins DI, Lifson JD, Reilly C, Carlis J, Haase AT. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis. 2006 Mar 1;193(5):703-12. doi: 10.1086/500368. Epub 2006 Jan 30.
  • Meigs JB, O’donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D’Agostino RB, Wilson PW. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes. 2006 Feb;55(2):530-7. doi: 10.2337/diabetes.55.02.06.db05-1041.
  • Januzzi JL Jr, Newby LK, Murphy SA, Pieper K, Antman EM, Morrow DA, Sabatine MS, Ohman EM, Cannon CP, Braunwald E. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J. 2006 Feb;151(2):360-6. doi: 10.1016/j.ahj.2005.04.021.
  • Smith EE, Cannon CP, Murphy S, Feske SK, Schwamm LH. Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes–Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J. 2006 Feb;151(2):338-44. doi: 10.1016/j.ahj.2005.03.031.
  • Nam BH, Kannel WB, D’Agostino RB. Search for an optimal atherogenic lipid risk profile: from the Framingham Study. Am J Cardiol. 2006 Feb 1;97(3):372-5. doi: 10.1016/j.amjcard.2005.08.055.
  • Loucks EB, Sullivan LM, D’Agostino RB Sr, Larson MG, Berkman LF, Benjamin EJ. Social networks and inflammatory markers in the Framingham Heart Study. J Biosoc Sci. 2006 Nov;38(6):835-42. doi: 10.1017/S0021932005001203. Epub 2006 Jan 27.
  • Loucks EB, Sullivan LM, Hayes LJ, D’Agostino RB Sr, Larson MG, Vasan RS, Benjamin EJ, Berkman LF. Association of educational level with inflammatory markers in the Framingham Offspring Study. Am J Epidemiol. 2006 Apr 1;163(7):622-8. doi: 10.1093/aje/kwj076. Epub 2006 Jan 18.
  • Januzzi JL, Thompson BT, Tung R. Letter regarding article by Brueckmann et al, “prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis”. Circulation. 2006 Jan 17;113(2):e25; author reply e25. doi: 10.1161/CIRCULATIONAHA.105.583294.
  • Jonas M, Stone GW, Mehran R, Hermiller J, Feldman R, Herrmann HC, Cox DA, Kuntz RE, Popma JJ, Rogers C; FilterWire EX Randomized Evalulation (FIRE) Investigators. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J. 2006 Apr;27(8):920-8. doi: 10.1093/eurheartj/ehi736. Epub 2006 Jan 16.
  • Ellis SG, Popma JJ, Stone GW, Russell ME. Restenosis, statistics, and reasonable inferences. J Am Coll Cardiol. 2006 Jan 17;47(2):470-1; author reply 471. doi: 10.1016/j.jacc.2005.10.035.
  • Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D’Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med. 2006 Jan 9;166(1):106-11. doi: 10.1001/archinte.166.1.106.
  • Moya FR, Sinha SK, D’Agostino R. Surfactant trials. Pediatrics. 2006 Jan;117(1):245-7; author reply 247-8. doi: 10.1542/peds.2005-1927.
  • Kratz A, Wood MJ, Siegel AJ, Hiers JR, Van Cott EM. Effects of marathon running on platelet activation markers : direct evidence for in vivo platelet activation. Am J Clin Pathol. 2006 Feb;125(2):296-300. doi: 10.1309/PRF5-N7P2-XM6E-243H.
  • Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006 Jan 3;47(1):91-7. doi: 10.1016/j.jacc.2005.08.051. Epub 2005 Dec 9.
  • Singh M, Williams BA, Gersh BJ, McClelland RL, Ho KK, Willerson JT, Penny WF, Cutlip DE, Holmes DR Jr. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. J Am Coll Cardiol. 2006 Jan 3;47(1):34-9. doi: 10.1016/j.jacc.2005.07.066.
  • Fox CS, Larson MG, Vasan RS, Guo CY, Parise H, Levy D, Leip EP, O’donnell CJ, D’Agostino RB Sr, Benjamin EJ. Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol. 2006 Feb;17(2):521-7. doi: 10.1681/ASN.2005060627. Epub 2005 Dec 28.
  • D’Agostino RB, Campbell MJ, Greenhouse JB. Surrogate markers: back to the future. Stat Med. 2006 Jan 30;25(2):181-2. doi: 10.1002/sim.2492.
  • Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, D’Agostino RB, Vasan RS, Robins SJ. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006 Jan 3;113(1):20-9. doi: 10.1161/CIRCULATIONAHA.105.567107. Epub 2005 Dec 27.
  • Feldman CL, Coskun AU, Yeghiazarians Y, Kinlay S, Wahle A, Olszewski ME, Rossen JD, Sonka M, Popma JJ, Orav J, Kuntz RE, Stone PH. Remodeling characteristics of minimally diseased coronary arteries are consistent along the length of the artery. Am J Cardiol. 2006 Jan 1;97(1):13-6. doi: 10.1016/j.amjcard.2005.07.121. Epub 2005 Nov 4.
  • de Figueiredo JM, Boerstler H, Doros G. Recent treatment history vs clinical characteristics in the prediction of use of outpatient psychiatric services. Soc Psychiatry Psychiatr Epidemiol. 2006 Feb;41(2):130-9. doi: 10.1007/s00127-005-0999-6. Epub 2006 Jan 1.
  • Baggish AL, Siebert U, Lainchbury JG, Cameron R, Anwaruddin S, Chen A, Krauser DG, Tung R, Brown DF, Richards AM, Januzzi JL Jr. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J. 2006 Jan;151(1):48-54. doi: 10.1016/j.ahj.2005.02.031.
  • Sabatine MS, Morrow DA, McCabe CH, Antman EM, Gibson CM, Cannon CP. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J. 2006 Jan;151(1):25-31. doi: 10.1016/j.ahj.2005.02.030.
  • Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006 Feb;27(3):330-7. doi: 10.1093/eurheartj/ehi631. Epub 2005 Nov 17.